Am J Transplant, Volume 17, Suppl 3 Archives - Page 181 of 181 - ATC Abstracts

2017 American Transplant Congress
Confirmation of the Safety of Cryopreserved Human Cord Blood Derived Di-Chimeric Cells in the NSG Mouse Model.
J. Cwykiel, N. Filipek, E. Szilagyi, E. Tfaily, M. Siemionow.
Orthopaedics, University of Illinois at Chicago, Chicago, IL
Background: Cell therapies are a promising approach for tolerance induction in Vascularized Composite Allotransplantation (VCA). Thus, we have developed a new supportive therapy of ex…
2017 American Transplant Congress
Activation of Inflammation Amplifier in Kidney Graft and Urinary Biomarker for Chronic Rejection.
H. Higuchi,^1,2 D. Iwami,¹ K. Hotta,¹ N. Shinohara,¹ M. Murakami.²
¹Hokkaido University, Renal and Genitourinary Surgery, Sapporo, Hokkaido, Japan; ²Hokkaido University, Molecular Neuroimmunology, Institute of Genetic Medicine, Graduate School of Medicine, Sapporo, Hokkaido, Japan
[Introduction and Objective] Inflammation amplifier (IA), a local chemokine inducer in non-immune cells is induced by simultaneous activation of NFκB and STATs (IL-17, TNFα, and…
2017 American Transplant Congress
Protective Effect of New Delivery System of Nitric Oxide Releasing Nanofiber in Rat Model of Renal Ischemia-Reperfusion Injury.
J. Kim,¹ H. Ahn,² D. Kim,¹ S. Jung,¹ E. Park,¹ T. Lee,¹ C. Ihm,¹ S. Lee,¹ J. Moon,¹ Y. Kim,¹ K. Jeong.¹
¹Nephrology, Kyung Hee University Medical Center, Seoul, Korea; ²Surgery, Kyung Hee University Medical Center, Seoul, Korea
Objective: Renal ischemia-reperfusion injury (IRI) is very important in various clinical setting including kidney transplantation. Nitric oxide (NO) is well known for having various protective…
2017 American Transplant Congress
Split Liver Ex-situ Oxygenated Machine Perfusion: A Novel Approach to Organ Preservation and Treatment.
N. Karimian,¹ V. Huang,¹ S. Geerts,¹ S. Mert,¹ I. Beijert,² F. Fontan,¹ M. Aburawi,¹ R. Porte,² K. Uygun,¹ J. Markmann,¹ H. Yeh.¹
¹Division of Transplantation, Massachusetts General Hospital, Boston; ²Division of Transplantation, University Medical Center Groningen, Groningen, Netherlands
Ex-situ machine perfusion (MP) is a promising method to improve organ viability prior to transplantation and is being used in various clinical trials worldwide. However,…
2017 American Transplant Congress
Immunosuppression (IS) Withdrawal (ISW) After ATG and Rituximab in Kidney Transplant Recipients (KTR): RESTARRT Early Results (NCT01318915).
B. Burrell,¹ J. Bromberg,² C. Hartono,³ A. Posselt,⁴ A. Naji,⁵ D. Kaufman,⁶ R. Redfield III,⁶ S. Kanaparthi,¹ D. Ikle,⁷ K. Much,⁷ N. Bridges,⁸ L. Sun,¹ A. Priore,⁸ M. DesMarais,¹ K. Crisalli,⁹ S. Chandran,¹ J. Markmann.⁹
¹ITN, Bethesda/San Francisco; ²UMD, Baltimore; ³Rogosin, New York; ⁴UCSF, San Francisco; ⁵UPenn, Philadelphia; ⁶UWisconsin, Madison; ⁷Rho, Chapel Hill; ⁸NIAID/NIH, Bethesda; ⁹MGH, Boston
Growing evidence implicates B cells in transplant tolerance. RESTARRT is a 6-center ISW study in adult living-related-donor KTR receiving ATG induction and rituximab with a…
2017 American Transplant Congress
Once-Daily versus Twice-Daily Tacrolimus in Living Kidney Transplantation: A Multicenter, Parallel Group, Open-Label, 5-Year, Randomized Non-Inferiority Trial.
K. Unagami,¹ M. Okumi,² T. Hirai,² D. Toki,³ H. Shirakawa,⁴ T. Shimizu,² K. Omoto,⁵ M. Inui,³ H. Ishida,² K. Nitta,¹ K. Tanabe.²
¹Nephrology, Tokyo Women's Medical University, Tokyo, Japan; ²Urology, Tokyo Women's Medical University, Tokyo, Japan; ³Urology, Tokyo Women's Medical University Yachiyo Medical Center, Yachiyo, Japan; ⁴Urology, Ohkubo Hospital, Tokyo, Japan; ⁵Transplant Surgery, Toda Chuo General Hospital, Toda, Japan
Background:Tacrolimus (TAC)-based induction therapy appears to be the standard immunosuppressive regimen for most kidney transplantation recipients (KTRs). TAC is available as a twice-daily (TAC-BID) and…